Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Heinemann

Showing results (91-100 of 185) with videos related to

Pageof 19
Sort By:
Cancer Research|February 1, 1992
Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiationV Heinemann, Y Z Xu, S Chubb, et al.
Oncology Reports|April 6, 2006
Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancerH J Stemmler, M Schmitt, N Harbeck, et al.
MMW Fortschritte Der Medizin|February 28, 2008
[Metastatic breast cancer--surgical possibilities]I Bauerfeind, S Kahlert, B Löhrs, et al.
Molecular Pharmacology|October 1, 1990
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidineV Heinemann, Y Z Xu, S Chubb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2007
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trialS Lorenzen, M Hentrich, C Haberl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2016
Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical courseS Boeck, Y Mehraein, S Ormanns, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1997
Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patientsV Heinemann, D Bosse, U Jehn, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1997
Serum pharmacology of amphotericin B applied in lipid emulsionsV Heinemann, B Kähny, U Jehn, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|April 27, 2002
[Surgical therapy of locally advanced and primary inoperable pancreatic carcinoma after neoadjuvant preoperative radiochemotherapy]H G Rau, M W Wichmann, R Wilkowski, et al.
British Journal of Cancer|January 14, 2010
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancerT Trarbach, M Moehler, V Heinemann, et al.
Pageof 19

Showing results (91-100 of 185) with videos related to

Sort By:
Pageof 19
Cancer Research|February 1, 1992
Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiationV Heinemann, Y Z Xu, S Chubb, et al.
Oncology Reports|April 6, 2006
Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancerH J Stemmler, M Schmitt, N Harbeck, et al.
MMW Fortschritte Der Medizin|February 28, 2008
[Metastatic breast cancer--surgical possibilities]I Bauerfeind, S Kahlert, B Löhrs, et al.
Molecular Pharmacology|October 1, 1990
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidineV Heinemann, Y Z Xu, S Chubb, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 31, 2007
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trialS Lorenzen, M Hentrich, C Haberl, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2016
Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical courseS Boeck, Y Mehraein, S Ormanns, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1997
Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patientsV Heinemann, D Bosse, U Jehn, et al.
Antimicrobial Agents and Chemotherapy|April 1, 1997
Serum pharmacology of amphotericin B applied in lipid emulsionsV Heinemann, B Kähny, U Jehn, et al.
Der Chirurg; Zeitschrift Fur Alle Gebiete Der Operativen Medizen|April 27, 2002
[Surgical therapy of locally advanced and primary inoperable pancreatic carcinoma after neoadjuvant preoperative radiochemotherapy]H G Rau, M W Wichmann, R Wilkowski, et al.
British Journal of Cancer|January 14, 2010
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancerT Trarbach, M Moehler, V Heinemann, et al.
Pageof 19